Ninane J, Perilongo G, Stalens J P, Guglielmi M, Otte J B, Mancini A
Department of Pediatric Hematology and Oncology, Cliniques Universitaires St. Luc, Brussels, Belgium.
Med Pediatr Oncol. 1991;19(3):199-203. doi: 10.1002/mpo.2950190310.
Sixteen children, aged 16 days to 13 years with hepatoblastoma (HB) (13 patients) or hepatocellular carcinoma (HCC) (3 patients), were given a total of 89 courses of cisplatin and doxorubicin (PLADO) as IV continuous infusion. All tumors were confined to the liver except for 1 hepatoblastoma patient with pulmonary metastases at presentation. Tumor response to PLADO was evaluable in 10 children (8 HB, 2 HCC) treated with preoperative chemotherapy and in another 2 HB patients treated when they developed pulmonary metastases after initial treatment with surgery alone. There were 2 complete responses (2 HB with pulmonary recurrences), 7 very good partial responses (6 HB and 1 HCC), 2 partial responses (1 HB, 1 HCC), and 1 stable disease (HB). The last patient underwent orthotopic liver transplantation whereas all the other patients had their tumor completely excised at delayed surgery. Documented toxicity was BM depression (16 patients), infection (11), vomiting (11), mucositis (3), hearing loss (1), and cardiotoxicity (1). These data indicate that PLADO in continuous infusion is effective in the treatment of malignant epithelial liver tumors with acceptable toxicity.
16名年龄在16天至13岁之间的儿童，患有肝母细胞瘤（HB）（13例）或肝细胞癌（HCC）（3例），共接受了89个疗程的顺铂和阿霉素（PLADO）静脉持续输注治疗。除1例初诊时伴有肺转移的肝母细胞瘤患儿外，所有肿瘤均局限于肝脏。对10名接受术前化疗的儿童（8例HB，2例HCC）以及另外2例在单纯手术初始治疗后出现肺转移时接受治疗的HB患儿，评估了肿瘤对PLADO的反应。有2例完全缓解（2例HB伴肺复发），7例非常好的部分缓解（6例HB和1例HCC），2例部分缓解（1例HB，1例HCC），以及1例病情稳定（HB）。最后1例患者接受了原位肝移植，而所有其他患者在延迟手术时肿瘤均被完全切除。记录的毒性反应包括骨髓抑制（16例）、感染（11例）、呕吐（11例）、粘膜炎（3例）、听力丧失（1例）和心脏毒性（1例）。这些数据表明，持续输注PLADO对治疗恶性上皮性肝肿瘤有效，且毒性可接受。
